TZ 101

Drug Profile

TZ 101

Alternative Names: ASC-101; Ftv1+Gdp-Fucose; GDP-fucose protein O-fucosyltransferase 1 - Targazyme; Peptide-O-fucosyltransferase - Targazyme; TZ101

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator America Stem Cell
  • Developer America Stem Cell; Indiana University School of Medicine; Oregon Health & Science University; Targazyme; University of California, San Diego; University of Texas M. D. Anderson Cancer Center; Wake Forest University School of Medicine
  • Class Fucosyltransferases; Hexosyltransferases
  • Mechanism of Action Fucosyltransferase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haematological malignancies; Graft-versus-host disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Graft-versus-host disease; Haematological malignancies
  • Preclinical Leukaemia; Multiple myeloma
  • No development reported Diabetic retinopathy; Multiple sclerosis; Muscle injury; Myelodysplastic syndromes; Myocardial infarction; Peripheral ischaemia; Stomatitis
  • Discontinued Autoimmune disorders; Bone metastases; Stroke

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Diabetic-retinopathy in USA (IV)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Muscle injury in USA (IV)
  • 25 Apr 2017 M.D. Anderson Cancer Center completes a phase I/II trial in Haematological malignancies in USA (Parenteral) (NCT01471067)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top